Platinum-Sensitive Ovarian Cancer Spotlight on Unmet Need
The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-sensitive ovarian cancer, where platinum-based regimens used to be the standard of care. Although substantial improvements have been made with the FDA’s 2019 approval of Lynparza for first-line maintenance therapy in advanced ovarian cancer, opportunity exists to develop more effective therapies for platinum-sensitive disease, while optimal sequencing of these therapies remains an unmet need.
QUESTIONS ANSWERED
- What are the treatment drivers and goals in surveyed medical oncologists’ prescribing decisions? What are the hidden opportunities that developers could leverage?
- How do current therapies, such as the PARP inhibitors, perform on key clinical attributes for this patient population?
- What are the greatest areas of unmet need and most attractive opportunities for platinum-sensitive ovarian cancer?
- What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles?
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in June 2020
Key companies: AstraZeneca, GSK, Clovis Oncology
Key drugs: Lynparza, Zejula, Rubraca
